Answers are grounded in this paper and cite their sources.
It is essential that diagnostic screening for Colon cancer [CC], which is the process of looking for the disease in people showing no symptoms for malignancy, needs to be carried out on at the early stages of malignancy, in order to reduces mortality from this curable cancer, if it could be detected at the earliest possible stage of the disease by an accurate and cost effective diagnostic measures, as it is ascertained that mortality from this curable malignancy is preventable through an early effective screening paradigm.There are presently several CC screening methods: the immunological fecal occult blood test [FOBTi] is known to lack sensitivity and has stringent dietary requirements, which decrease compliance.The gold standard for CC screening is "colonoscopy", is invasive and also costly, thus decreasing compliance, and could lead to mortality in some cases.Therefore, it has been correctly envisioned that a noninvasive sensitive screen, which does not require dietary restriction, would be a more convenient screening strategy.Colonoscopy screening is currently recommended for colorectal cancer [CRC].Although it is a reliable screening method, it is an invasive procedure, usually accompanied by an abdominal pain, has potential serious complications and is relatively expensive, all are factors that have hampered its Worldwide application.A screening approach that employs the relatively stable and non-degradable micro[mi]RNA molecules when extracted from either the noninvasive human stool, or the semi-invasive blood samples by available commercial kits and manipulated thereafter, would therefore be more reliable than transcriptomic messenger [m]RNA-, mutation DNA-, epigenetic-and/or proteomic-based tests.The miRNA approach utilizes reverse transcriptase [RT], followed by a modified quantitative real-time polymerase chain reaction [qPCR].In order to compensate for exosomal miRNAs, which are not measured by this test, a parallel test need to also be performed on stool or plasma's total RNAs, and corrections for exsosomal loss made in order to obtain accurate results.Ultimately, a chip needs to be developed to facilitate diagnosis, as has been used for the quantification of genetically modified organisms [GMOs] in foods.The gold standard to which the miRNA test is compared to should be colonoscopy examination.If good laboratory performance criteria are met, then a miRNA test in human stool or blood samples --based on high throughput automated technologies and quantitative expression measurements currently employed in the diagnostic clinical laboratory--would ultimately be advanced to the clinical setting, making a Worldwide noticeable impact on the prevention of colon cancer.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2017) studied this question.
Synapse has enriched 3 related papers. Consider them for comparative context: